ABI-231 HCl - CAS 2635953-17-0

ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. ABI-231, has an average IC50 = 5.2 nM against panels of melanoma and prostate cancer cell lines, is orally bioavailable, and strongly suppress melanoma tumors in vivo. ABI-231 holds great promise as a new generation of orally available tubulin inhibitor.

Others, Microtubule Associated, Endogenous Metabolite, Apoptosis, Virus Protease

Cytoskeletal Signaling, Others, Apoptosis, Metabolism, Microbiology/Virology

2635936

C21H20ClN3O4

413.85

C(=O)(C=1NC(C=2C=3C(NC2)=CC=CC3)=NC1)C4=CC(OC)=C(OC)C(OC)=C4.Cl

-20°C

Ice Packs

Small Compound